Bevacizumab does not inhibit the formation of liver vessels and liver regeneration following major hepatectomy: a large animal model study

O Troup, A Skalicky, L Vistejnova, P Klein, A Maleckova… - in vivo, 2022 - iv.iiarjournals.org
Background/Aim: Patients with unresectable liver colorectal cancer metastases are treated
with neoadjuvant chemotherapy often accompanied by biological therapy aimed at reducing …

Bevacizumab impairs hepatocyte proliferation after partial hepatectomy in a rabbit model

A Dupre, A Paradisi, S Langonnet, A Gandini… - Anticancer …, 2012 - ar.iiarjournals.org
Background: Bevacizumab is used to treat patients with metastatic colorectal cancer,
including those who will undergo liver surgery. The effects of this agent on the regenerative …

The impact of bevacizumab on liver regeneration following hepatectomy in rats.

H Mori, M Shimada, T Utsunomiya, S Imura… - Journal of Clinical …, 2011 - ascopubs.org
228 Background: In our clinical data, we had the interesting findings that the pathologic
sinusoidal obstruction syndrome and serum hyaluronic acid after neoadjuvant oxaliplatin …

Preoperative bevacizumab and volumetric recovery after resection of colorectal liver metastases

GA Margonis, S Buettner, N Andreatos… - Journal of surgical …, 2017 - Wiley Online Library
Background and Objectives While preoperative treatment is frequently administered to
CRLM patients, the impact of chemotherapy, with or without bevacizumab, on liver …

[HTML][HTML] Administration of anti-vascular endothelial growth factor antibody following hepatectomy does not inhibit remnant liver regeneration or growth of remnant …

K Kasuya, M Suzuki, Y Nagakawa… - Experimental and …, 2012 - spandidos-publications.com
In addition to the use of chemotherapeutic agents for the prevention of multiple liver
metastases from colorectal cancer, the anti-vascular endothelial growth factor (VEGF) …

[PDF][PDF] Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab

LM Ellis, SA Curley, A Grothey - Journal of Clinical Oncology, 2005 - academia.edu
During the last 5 years, numerous publications have demonstrated the potential value of
chemotherapy in downstaging patients with hepatic metastasis from colorectal cancer …

[HTML][HTML] Impact of Bevacizumab on parenchymal damage and functional recovery of the liver in patients with colorectal liver metastases

AM Volk, J Fritzmann, C Reissfelder, GF Weber, J Weitz… - BMC cancer, 2016 - Springer
Background Little is known about the safety of the anti-VEGF antibody bevacizumab in
patients undergoing resection for colorectal liver metastases (CLM). This meta-analysis …

Bevacizumab allows preservation of liver function and its regenerative capacity after major hepatectomy

A Valverde, R Ciria… - Anti-Cancer Agents …, 2019 - ingentaconnect.com
Background: Parallel to the safety of liver resections, new chemotherapy drugs have
emerged for the control of liver metastases. However, there is unclear evidence about the …

Postoperative liver function recovery after hepatic resection for colorectal metastases previously treated with bevacizumab

R Adam, DA Wicherts, RJ de Haas, F Lévi… - Journal of Clinical …, 2009 - ascopubs.org
4093 Background: The influence of bevacizumab on postoperative morbidity in patients with
colorectal liver metastases (CLM) submitted to hepatectomy has been evaluated. However …

[HTML][HTML] Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation

P Starlinger, L Alidzanovic, D Schauer, T Maier… - British journal of …, 2012 - nature.com
Background: When anti-VEGF (vascular endothelial growth factor) antibody bevacizumab is
applied in neoadjuvant treatment of colorectal cancer patients with liver metastasis, 5–6 …